Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 3/20 | 0.55 |
| ▸ | MAP3K7 | O43318 | 2/20 | 0.55 |
| ▸ | MAP4K2 | Q12851 | 2/20 | 0.55 |
| ▸ | MAP3K20 | Q9NYL2 | 2/20 | 0.55 |
| ▸ | NR2C2 | P49116 | 3/20 | 0.54 |
| ▸ | BTK | Q06187 | 2/20 | 0.54 |
| ▸ | HTT | P42858 | 3/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | ATM | Q13315 | 1/20 | 0.54 |
| ▸ | HCK | P08631 | 3/20 | 0.54 |
| ▸ | CLK1 | P49759 | 1/20 | 0.53 |
| ▸ | EGFR | P00533 | 1/20 | 0.53 |
| ▸ | BRAF | P15056 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14011570 | 0.92 | NR2C2 (0.59) | MAPK14MAP3K7MAP4K2MAP3K20NR2C2 | |
| SCHEMBL10043661 | 0.86 | SYK (0.55) | MAPK14MAP4K2HTTBRAF | |
| SCHEMBL1134923 | 0.85 | MAPK14 (0.63) | MAPK14MAP3K7MAP4K2MAP3K20ATM | |
| SCHEMBL10043751 | 0.84 | SYK (0.53) | MAPK14MAP4K2BRAF | |
| SCHEMBL10043758 | 0.83 | LCK (0.53) | MAPK14MAP4K2BTKBRAF | |
| SCHEMBL502521 | 0.83 | BRAF (0.61) | MAP4K2HCKBRAF | |
| SCHEMBL14011585 | 0.82 | BRAF (0.50) | MAPK14MAP3K7MAP4K2MAP3K20NR2C2 | |
| SCHEMBL10043720 | 0.81 | SYK (0.47) | MAPK14MAP4K2HTTBRAF | |
| SCHEMBL4869570 | 0.80 | MAPK14 (0.60) | MAPK14MAP3K7MAP4K2MAP3K20NR2C2 | |
| SCHEMBL4879660 | 0.80 | EGFR (0.58) | MAPK14MAP3K7MAP4K2MAP3K20NR2C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8106068-B2 | Compositions and methods for modulating c-kit and PDGFR receptors | IRM LLC (BM) | 2012-01-31 | — | — | US | disclosed |
| US-20100081656-A1 | COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS | IRM LLC (BM) | 2010-04-01 | — | — | US | disclosed |
| US-7678792-B2 | Compositions and methods for modulating c-kit and PDGFR receptors | IRM LLC (BM) | 2010-03-16 | — | — | US | disclosed |
| US-7678792-B2 | Compositions and methods for modulating c-kit and PDGFR receptors | IRM LLC (BM) | 2010-03-16 | — | — | US | disclosed |
| US-20080176846-A1 | COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS | IRM LLC (BM) | 2008-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176846-A1 | COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS | FYN, FLT3, SRC | MAPK14 117/4885MAP3K7 21/4885MAP4K2 17/4885 |
| US-20100081656-A1 | COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS | FYN, FLT3, SRC | MAPK14 117/4885MAP3K7 21/4885MAP4K2 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.